Lite Strategy LITS

Lite Strategy, Inc. is a pharmaceutical company focused on developing novel cancer therapies through strategic acquisitions and clinical development. Formerly known as MEI Pharma, Inc., the company rebranded in September 2025 to reflect a broader strategic shift toward integrating digital asset innovation with its oncology pipeline. Lite Strategy operates in the highly competitive oncology drug development sector, where it aims to address unmet medical needs by evaluating drug candidates in combination with standard-of-care therapies to overcome resistance mechanisms and improve patient outcomes. The company’s pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor, and zandelisib, a selective PI3Kδ inhibitor, though both programs are currently in preclinical assessment following the discontinuation of clinical trials.

Lite Strategy generates revenue primarily through strategic partnerships, licensing agreements, and the monetization of its drug development assets. Historically, the company has relied on upfront payments, milestone payments, and royalties from collaborations with pharmaceutical partners, such as its terminated global license agreement with Kyowa Kirin Co., Ltd. for zandelisib. In July 2025, the company raised $100.0 million through a private investment in public equity offering, which it subsequently deployed into a Litecoin Treasury Strategy to diversify its reserves and explore emerging financial technologies. This shift reflects an effort to enhance capital efficiency while maintaining a focus on preclinical oncology research and potential future out-licensing opportunities.

The company operates through the following segments.

• Oncology Drug Development: This segment focuses on the preclinical and clinical evaluation of novel cancer therapies, including voruciclib and zandelisib. Voruciclib, a CDK9 inhibitor, was previously in Phase 1 trials for acute myeloid leukemia in combination with venetoclax but was discontinued in July 2024. Zandelisib, a PI3Kδ inhibitor, was jointly developed with Kyowa Kirin until the global termination of its development program in 2023. The company continues to assess preclinical opportunities for both candidates in oncology and non-oncology indications.
• Digital Asset and Treasury Strategy: Introduced in August 2025, this segment involves the deployment of capital into Litecoin and related digital asset infrastructure to diversify reserves and align with financial technology innovation. The strategy includes potential Litecoin mining activities and partnerships with asset managers and custodians to optimize capital efficiency. This segment represents a pivot from traditional biopharmaceutical revenue models toward long-term capital innovation.

Lite Strategy operates in the highly competitive oncology drug development industry, where it faces challenges from larger pharmaceutical and biotechnology companies with greater resources, established pipelines, and commercialization expertise. Key competitors include firms developing CDK9 and PI3Kδ inhibitors, as well as companies targeting similar resistance mechanisms in cancer therapy. The company’s competitive advantages lie in its intellectual property portfolio, which includes issued and pending patents covering voruciclib and zandelisib, and its strategic approach to combination therapies. However, its limited financial resources, small workforce, and recent discontinuation of clinical programs position it as a high-risk, early-stage player in the sector. The shift toward digital asset strategies may provide a unique differentiator but introduces additional volatility and regulatory uncertainty.

The company’s customer base primarily consists of pharmaceutical partners, academic institutions, and regulatory agencies involved in drug development and commercialization. Historically, Lite Strategy has collaborated with companies such as Kyowa Kirin Co., Ltd. for the development of zandelisib, though such partnerships have since been terminated. Its preclinical and clinical programs target patients with hematological malignancies and solid tumors, including acute myeloid leukemia and non-Hodgkin lymphoma. The company does not currently serve end consumers directly, as its drug candidates remain in early-stage development or preclinical assessment.